The Avacta share price is down 15% from its highs. Would I buy it now?

The Avacta share price is down from its highs, but is that reason to buy the stock? Or should the investor dig deeper into this story?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When a high-performing share’s price falls from its highs, it is tempting to ask if I should buy the dip. This is the case now with biotechnology stock Avacta (LSE: AVCT). The Avacta share price has just dropped 15% from its all-time highs in less than two weeks. 

But before I buy the high-performing stock, I would like to ask three questions. These are:

#1. Why did the Avacta share price rise?

The Avacta share price first started rising in early April last year when it collaborated with Cytiva, which was earlier GE Healthcare Life Sciences, to develop coronavirus diagnosis tests. Unlike tests available until then, the rapid test would give results within minutes. 

This development gave the stock sharp momentum for around two months, before it settled at elevated levels compared to the pre-pandemic share price. Until early 2021, that is. 

In February this year, the Avacta share price showed another sharp climb when it received positive results for clinical studies on its tests. The initial evaluation allowed it to move to the full clinical validation of the tests. 

Then towards the end of the month, the company released a business update with optimism about the commercial potential of the coronavirus test, keeping the momentum up. And in early March the company said that its test can detect coronavirus variants found in the UK as well.

#2. What are the prospects for it?

That is a lot of positive developments for a company in a short span of time. Considering how important coronavirus tests are and will be for the foreseeable future, Avacta could well be in a sweet spot. 

I also like that it is developing therapies for cancer through its proprietary platforms. It aims to start providing its chemotherapy treatments in the first half of this year, which target achieving a more durable response in patients than existing treatments.  

These steps reflect the company’s growth, and this could well be the year that proves to be a turning point. So far however, it has made losses and its revenue has been somewhat inconsistent too.

#3. What are the risks to the Avacta share price?

There are a number of companies working on various coronavirus-related solutions, from vaccines to diagnosis and treatment. As an investor, if I am looking to buy these, I would consider this entire spectrum. And a reminder here, this includes some of the biggest FTSE companies, like AstraZeneca, and US-based ones like Pfizer

Alternatively, I can consider it if I wanted to buy shares of a company that promises fast growth. But here too, better performing companies can be found. 

What I’d do now

My point is that my reason for buying the Avacta share should be clear. If it is not, then I would rather wait for some proof of progress in its financials than be tempted today by the Avacta share price. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Manika Premsingh owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

How I’d invest £5,000 in FTSE 100 shares to aim for a million

The FTSE 100 is home to many potential gems. Our writer considers if he can reach millionaire status by uncovering…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

How I’m aiming to become a Stocks and Shares ISA millionaire!

The Stocks and Shares ISA is an excellent vehicle for investments. In fact, many investors have become ISA millionaires. Here's…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

The Scottish Mortgage share price is on the up! Here’s why I’d buy

After a poor first half of the year, the Scottish Mortgage share price is beginning to rise. Here, this Fool…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Should I be grabbing cheap Lloyds shares?

Lloyds shares have underperformed in recent years. Here, this Fool explains why he's still considering the stock for his portfolio.

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

How I’m using UK dividend shares to try and turn £20,000 into £100,000

Our writer has ambitious investment goals -- and patience. Here he explains how he's buying UK dividend shares to try…

Read more »

Middle-aged lady in wheelchair writing on whiteboard
Investing Articles

I’m taking a defensive stance by investing in the FTSE ahead of the recession

The FTSE has outperformed several indices in 2022, including the S&P 500. Jacob Ambrose Willson believes it can be used…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Should I buy BP shares today?

BP is generating huge profits right now. Here, Edward Sheldon looks at whether he should buy shares in the oil…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Should I buy Rolls-Royce shares after the latest results?

Jon Smith runs over the key points from half-year results for Rolls-Royce shares to see if any green shoots are…

Read more »